Diadem Biotherapeutics
Engineering the next class of biologics to treat chronic inflammatory diseases
Operating in biopharma based in United States, Diadem Biotherapeutics was founded in 2019.
Profile
Diadem Biotherapeutics (Diadem) engineers signalling proteins to display on the surface of cell-derived vesicles (exosomes) to treat cancer, chronic inflammation and autoimmune diseases. Diadem’s engineered exosomes mimic natural cell signaling in an agonist (activating) manner through clinically validated immune checkpoint receptors that play a role in autoimmune diseases or immune control of cancer.
Within the biopharma space, the company focuses on its core offering rather than a broad product line.
Its base of operations is United States.
It is recorded at the SOSV portfolio company stage.
The company reports a headcount in the 2-10 range.
| Sector | Biopharma |
|---|---|
| Country | United States |
| Founded | 2019 |
| Employees | 2-10 |
| Stage | SOSV portfolio company |
Website: diadembio.com
Create a free account